Leadership Built to Commercialize Regulated AI at Scale

Dr. Mauldin serves as Chairman and Chief Executive Officer of RIVANNA, where he leads the commercialization of the company’s imaging-based AI clinical decision-support platform across global healthcare markets. Under his leadership, RIVANNA has secured over $90 million in funding, achieved multiple FDA 510(k) clearances, expanded international distribution, and earned recognition as a MedTech Innovator finalist. Dr. Mauldin has guided the company from early development into a phase of commercial execution and value realization, with a focus on scalable deployment, clinical adoption, and enterprise growth. His work has resulted in a strong intellectual property position with over 100 patents supporting RIVANNA’s platform. Dr. Mauldin earned a doctorate in biomedical engineering from the University of Virginia and a bachelor’s degree in applied science from the University of North Carolina at Chapel Hill.

Dr. Dixon leads technology development, clinical translation, and commercialization at RIVANNA. His career spans the development and commercialization of advanced imaging platforms at GE Healthcare and RIVANNA, including the Logiq E9 (ultrasound), Lightspeed 750HD (computed tomography), and Precision 180 (fluoroscopy) at GE, and RIVANNA’s flagship Accuro (ultrasound). He has co-authored numerous peer-reviewed articles and patents and secured significant SBIR funding to support RIVANNA’s technology development and commercialization efforts. Under his technical leadership, every SBIR granted to RIVANNA has resulted in a commercialized product or significant follow-on funding, most recently culminating in FDA 510(k) clearances for RIVANNA’s leading regional anesthesia and fracture care platforms. Dr. Dixon holds a doctorate in biomedical engineering from the University of Virginia and an undergraduate degree from Duke University.

Mike provides the financial infrastructure underpinning the company’s growth and commercial ramp. He brings over a decade of finance and accounting experience, including a career at Deloitte’s Audit & Assurance practice, where he achieved the title of senior manager. His expertise spans financial reporting and technical accounting, including a two-year rotation at Deloitte’s London office supporting clients in raising capital through public debt and equity offerings in the US and UK, as well as advising on mergers, acquisitions, and go-public transactions. Before joining RIVANNA, Mike served as vice president controller at a private equity-backed telemedicine organization, where he led company’s ERP implementation, established scalable financial and operational processes, and integrated acquired businesses to support rapid growth. He holds a B.S. in commerce from the University of Virginia.

Dr. Sheeran leads R&D, oversees IP strategy, coordinates grant-based clinical collaborations, and manages the company’s proprietary clinical datasets. He has contributed to numerous peer-reviewed publications and patents and has helped secure substantial SBIR funding to support RIVANNA’s technology development. Prior to RIVANNA, he worked at Philips Healthcare, leading product development efforts focused on 3D ultrasound imaging, contrast imaging, and workflow optimization. Notably, Dr. Sheeran introduced algorithmic enhancements that reduced workflow burden by up to 54% on the globally deployed EPIQ imaging platform. He holds a doctorate in biomedical engineering from the University of North Carolina at Chapel Hill and dual bachelor’s degrees in electrical and computer engineering from NC State. He was awarded the NSF Graduate Research Fellowship and held the Frederick Banting Postdoctoral Fellowship at Sunnybrook Research Institute.

Zach manages product strategy and roadmaps, leads hardware and manufacturing engineering, and oversees design transfer, manufacturing scale-up, and sustaining initiatives across RIVANNA’s product platforms. Prior to RIVANNA, he held engineering and leadership roles at Hewlett-Packard, Baker Hughes, and Asensus Surgical. At Asensus, he led mechanical development for key subsystems of the next-generation LUNA robotic surgery platform and managed the development of a major Senhance surgical system upgrade, delivering a cleared device and consumable to market. He has a proven track record in new product introduction and design transfer and holds over 10 patents. Zach earned a B.S. in mechanical engineering with a minor in business from Texas A&M University.